| Style | Citing Format |
|---|---|
| MLA | Khatami S, et al.. "The Effectiveness of a Topical Turmeric-Based Formulation on Contact Dermatitis: A Randomized, Double-Blind, Controlled Trial." Iranian Journal of Pharmaceutical Research, vol. 25, no. 1, 2026, pp. -. |
| APA | Khatami S, Sadati Lamardi S N, Najafi Vosough R, Mizani A, Shirbeigi L, Abbassian A (2026). The Effectiveness of a Topical Turmeric-Based Formulation on Contact Dermatitis: A Randomized, Double-Blind, Controlled Trial. Iranian Journal of Pharmaceutical Research, 25(1), -. |
| Chicago | Khatami S, Sadati Lamardi S N, Najafi Vosough R, Mizani A, Shirbeigi L, Abbassian A. "The Effectiveness of a Topical Turmeric-Based Formulation on Contact Dermatitis: A Randomized, Double-Blind, Controlled Trial." Iranian Journal of Pharmaceutical Research 25, no. 1 (2026): -. |
| Harvard | Khatami S et al. (2026) 'The Effectiveness of a Topical Turmeric-Based Formulation on Contact Dermatitis: A Randomized, Double-Blind, Controlled Trial', Iranian Journal of Pharmaceutical Research, 25(1), pp. -. |
| Vancouver | Khatami S, Sadati Lamardi S N, Najafi Vosough R, Mizani A, Shirbeigi L, Abbassian A. The Effectiveness of a Topical Turmeric-Based Formulation on Contact Dermatitis: A Randomized, Double-Blind, Controlled Trial. Iranian Journal of Pharmaceutical Research. 2026;25(1):-. |
| BibTex | @article{ author = {Khatami S and Sadati Lamardi S N and Najafi Vosough R and Mizani A and Shirbeigi L and Abbassian A}, title = {The Effectiveness of a Topical Turmeric-Based Formulation on Contact Dermatitis: A Randomized, Double-Blind, Controlled Trial}, journal = {Iranian Journal of Pharmaceutical Research}, volume = {25}, number = {1}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Khatami S AU - Sadati Lamardi S N AU - Najafi Vosough R AU - Mizani A AU - Shirbeigi L AU - Abbassian A TI - The Effectiveness of a Topical Turmeric-Based Formulation on Contact Dermatitis: A Randomized, Double-Blind, Controlled Trial JO - Iranian Journal of Pharmaceutical Research VL - 25 IS - 1 SP - EP - PY - 2026 ER - |